Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Vaccines

Free Subscription Articles published in Nat Med Retrieve available abstracts of 80 articles: HTML format

Single Articles

June 2026
1. O'LEARY K
   HPV vaccination linked to dramatic reduction in cervical cancer deaths.
   Nat Med. 2026 Jun 25. doi: 10.1038/d41591-026-00033.
   PubMed    
   
   
   
2. GELDSETZER P
   Why large-scale randomized trials of live-attenuated shingles vaccination for dementia prevention are urgently needed.
   Nat Med. 2026 Jun 17. doi: 10.1038/s41591-026-04474.
   PubMed    
   
   
   
3. NGONGO N, Fallah MP, Dereje N, Boum Y, et al
   Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures.
   Nat Med. 2026 Jun 9. doi: 10.1038/s41591-026-04482.
   PubMed    
   
   
   
4. ORTIZ JR, Kurup D, Kaufman AC, Ben Hamed S, et al
   Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial.
   Nat Med. 2026 Jun 9. doi: 10.1038/s41591-026-04429.
   PubMed     Abstract available
   
   
   
5. DE JONG SPJ, Russell CA
   Limited evidence of AI superiority in seasonal influenza vaccine strain selection.
   Nat Med. 2026 Jun 3. doi: 10.1038/s41591-026-04461.
   PubMed    
   
   
   
6. SHI W, Wohlwend J, Wu M, Barzilay R, et al
   Reply to: Limited evidence of AI superiority in seasonal influenza vaccine strain selection.
   Nat Med. 2026 Jun 3. doi: 10.1038/s41591-026-04460.
   PubMed    
   
   
   May 2026
7. CANFELL K
   HPV vaccines, 20 years on.
   Nat Med. 2026;32:1583-1585.
   PubMed    
   
   
   
8. KIM JH, Ndembi N
   Global vaccine development.
   Nat Med. 2026;32:1610-1622.
   PubMed     Abstract available
   
   
   March 2026
9. HAANEN JB, Schumacher TNM, Kagan JC, Fritsch EF, et al
   Publisher Correction: Clinical development of cancer vaccines.
   Nat Med. 2026 Mar 26. doi: 10.1038/s41591-026-04361.
   PubMed    
   
   
   
10. O'LEARY K
    One vaccine, no needles, broad protection.
    Nat Med. 2026 Mar 16. doi: 10.1038/d41591-026-00015.
    PubMed    
    
    
    
11. PLOQUIN A, Mason RD, Holman LA, Happe M, et al
    A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.
    Nat Med. 2026 Mar 12. doi: 10.1038/s41591-026-04265.
    PubMed     Abstract available
    
    
    
12. HAANEN JB, Schumacher TNM, Kagan JC, Fritsch EF, et al
    Clinical development of cancer vaccines.
    Nat Med. 2026 Mar 11. doi: 10.1038/s41591-026-04241.
    PubMed     Abstract available
    
    
    
13. MAY M
    Mosquito-borne viruses, vaccine-borne hope.
    Nat Med. 2026 Mar 9. doi: 10.1038/d41591-026-00014.
    PubMed    
    
    
    
14. KALLAS EG, Moreira JA, Patino EG, Braga PE, et al
    Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.
    Nat Med. 2026 Mar 4. doi: 10.1038/s41591-026-04255.
    PubMed     Abstract available
    
    
    February 2026
15. MURCIANO-GOROFF YR, Stadler ZK
    Preventive vaccines for hereditary cancer syndromes.
    Nat Med. 2026 Feb 26. doi: 10.1038/s41591-026-04248.
    PubMed    
    
    
    
16. WEISOVA P, Scheiblauer S, Ecker J, Schneider M, et al
    Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.
    Nat Med. 2026 Feb 6. doi: 10.1038/s41591-025-04197.
    PubMed     Abstract available
    
    
    January 2026
17. KIM K, Title B, Kipnis J
    Placebo effect influences vaccine responses.
    Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04168.
    PubMed    
    
    
    
18. LUBIANIKER N, Koren T, Djerasi M, Sirotkin M, et al
    Upregulation of reward mesolimbic activity and immune response to vaccination: a randomized controlled trial.
    Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04140.
    PubMed     Abstract available
    
    
    
19. D'ALISE AM, Willis J, Duzagac F, Hall MJ, et al
    Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.
    Nat Med. 2026 Jan 16. doi: 10.1038/s41591-025-04182.
    PubMed     Abstract available
    
    
    
20. RASMUSSEN AL
    US vaccine policy must put America first.
    Nat Med. 2026 Jan 9. doi: 10.1038/d41591-026-00002.
    PubMed    
    
    
    
21. KAPULU MC, Orenge F, Kimani D, Kibwana E, et al
    Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.
    Nat Med. 2026 Jan 6. doi: 10.1038/s41591-025-04107.
    PubMed     Abstract available
    
    
    
22. SIMONS D, Watson-Jones D, Manno D, Friant S, et al
    A One Health trial design to accelerate Lassa fever vaccines.
    Nat Med. 2026 Jan 2. doi: 10.1038/s41591-025-04018.
    PubMed    
    
    
    
23. WONG GL, Yuen MF, Lin B, Douglas MW, et al
    Elebsiran and PEG-IFNalpha for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
    Nat Med. 2026;32:151-159.
    PubMed     Abstract available
    
    
    December 2025
24. POLISKY V, Littmann M, Triastcyn A, Horn M, et al
    Varicella-zoster virus reactivation and the risk of dementia.
    Nat Med. 2025;31:4172-4179.
    PubMed     Abstract available
    
    
    November 2025
25. O'LEARY K
    A much-needed vaccine for Nipah virus.
    Nat Med. 2025 Nov 26. doi: 10.1038/d41591-025-00068.
    PubMed    
    
    
    
26. BARETTI M, Kirk AM, Ladle BH, Kamdar Z, et al
    A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.
    Nat Med. 2025 Nov 24. doi: 10.1038/s41591-025-03995.
    PubMed     Abstract available
    
    
    
27. RIBEIRO DOS SANTOS G, Jawed F, Mukandavire C, Deol A, et al
    Author Correction: Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.
    Nat Med. 2025 Nov 10. doi: 10.1038/s41591-025-04065.
    PubMed    
    
    
    October 2025
28. NAIR NP, Reddy SN, Giri S, Varghese T, et al
    Author Correction: Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.
    Nat Med. 2025 Oct 27. doi: 10.1038/s41591-025-04062.
    PubMed    
    
    
    
29. 
    Rotavirus vaccine reduces gastroenteritis hospitalizations in Indian children.
    Nat Med. 2025 Oct 15. doi: 10.1038/s41591-025-04034.
    PubMed    
    
    
    
30. KAMPMANN B, Hucko A
    Ebola vaccine safe for mothers and infants.
    Nat Med. 2025 Oct 9. doi: 10.1038/s41591-025-04000.
    PubMed    
    
    
    
31. CHEN WH, Barnes RS, Sikorski MJ, Datar R, et al
    A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2025 Oct 8. doi: 10.1038/s41591-025-04003.
    PubMed     Abstract available
    
    
    
32. NAIR NP, Reddy SN, Giri S, Thiyagarajan V, et al
    Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.
    Nat Med. 2025 Oct 7. doi: 10.1038/s41591-025-03998.
    PubMed     Abstract available
    
    
    September 2025
33. NYOMBAYIRE J, Ingabire R, Mazzei A, Sharkey T, et al
    Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.
    Nat Med. 2025 Sep 8. doi: 10.1038/s41591-025-03932.
    PubMed     Abstract available
    
    
    
34. CHU HY, Janes H, Carone M, Gilbert PB, et al
    Improving the evidence base for COVID-19 vaccines.
    Nat Med. 2025 Sep 4. doi: 10.1038/s41591-025-03908.
    PubMed    
    
    
    August 2025
35. O'LEARY K
    Aluminum in childhood vaccines not linked to chronic diseases.
    Nat Med. 2025 Aug 29. doi: 10.1038/d41591-025-00055.
    PubMed    
    
    
    
36. SHI W, Wohlwend J, Wu M, Barzilay R, et al
    Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model.
    Nat Med. 2025 Aug 28. doi: 10.1038/s41591-025-03917.
    PubMed     Abstract available
    
    
    
37. WAINBERG ZA, Weekes CD, Furqan M, Kasi PM, et al
    Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
    Nat Med. 2025 Aug 11. doi: 10.1038/s41591-025-03876.
    PubMed     Abstract available
    
    
    
38. KEELEY AJ, Camara FE, Armitage EP, de Crombrugghe G, et al
    Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.
    Nat Med. 2025 Aug 8. doi: 10.1038/s41591-025-03868.
    PubMed     Abstract available
    
    
    July 2025
39. ZITVOGEL L
    Rethinking chemotherapy as an indirect vaccine.
    Nat Med. 2025 Jul 24. doi: 10.1038/s41591-025-03804.
    PubMed    
    
    
    June 2025
40. 
    Chikungunya virus burden and implications for vaccination programs.
    Nat Med. 2025 Jun 27. doi: 10.1038/s41591-025-03812.
    PubMed    
    
    
    
41. CRACKNELL DANIELS B, Ferguson NM, Dorigatti I
    Efficacy, public health impact and optimal use of the Takeda dengue vaccine.
    Nat Med. 2025 Jun 25. doi: 10.1038/s41591-025-03771.
    PubMed     Abstract available
    
    
    
42. RIBEIRO DOS SANTOS G, Jawed F, Mukandavire C, Deol A, et al
    Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.
    Nat Med. 2025 Jun 10. doi: 10.1038/s41591-025-03703.
    PubMed     Abstract available
    
    
    
43. NDEMBI N, Mutesa L, Muvunyi CM, Kim JH, et al
    Bridging the vaccine divide.
    Nat Med. 2025 Jun 2. doi: 10.1038/s41591-025-03728.
    PubMed    
    
    
    May 2025
44. SHORE ND, Powles TB, Bedke J, Galsky MD, et al
    Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
    Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03738.
    PubMed     Abstract available
    
    
    
45. O'LEARY K
    Measles to become endemic in the USA if vaccination rates continue to fall.
    Nat Med. 2025 May 14. doi: 10.1038/d41591-025-00031.
    PubMed    
    
    
    
46. PEREZ-ESTIGARRIBIA PE, Ribeiro Dos Santos G, Cauchemez S, Vazquez C, et al
    Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks.
    Nat Med. 2025 May 1. doi: 10.1038/s41591-025-03684.
    PubMed     Abstract available
    
    
    
47. GARRETSON TA, Liu J, Li SH, Scher G, et al
    Immune history shapes human antibody responses to H5N1 influenza viruses.
    Nat Med. 2025;31:1454-1458.
    PubMed     Abstract available
    
    
    April 2025
48. O'LEARY K
    Antibiotics reduce vaccine responses in infants.
    Nat Med. 2025 Apr 30. doi: 10.1038/d41591-025-00028.
    PubMed    
    
    
    
49. 
    Combating vaccine revisionism.
    Nat Med. 2025 Apr 7. doi: 10.1038/s41591-025-03682.
    PubMed    
    
    
    
50. HOU Z, Wu Z, Qu Z, Gong L, et al
    A vaccine chatbot intervention for parents to improve HPV vaccination uptake among middle school girls: a cluster randomized trial.
    Nat Med. 2025 Apr 7. doi: 10.1038/s41591-025-03618.
    PubMed     Abstract available
    
    
    March 2025
51. RUDMAN SPERGEL AK, Ananworanich J, Guo R, Deng W, et al
    mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial.
    Nat Med. 2025 Mar 18. doi: 10.1038/s41591-025-03591.
    PubMed     Abstract available
    
    
    
52. ADAMU AA, Ndwandwe D, Wiysonge CS
    Leveraging implementation science in clinical trials of vaccines in the global south.
    Nat Med. 2025 Mar 5. doi: 10.1038/s41591-025-03546.
    PubMed    
    
    
    January 2025
53. DU Z, Pandey A, Moghadas SM, Bai Y, et al
    Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults.
    Nat Med. 2025 Jan 9. doi: 10.1038/s41591-024-03431.
    PubMed     Abstract available
    
    
    
54. GOSWAMI D, Kappe SHI
    Setting sights on a single-shot malaria vaccine.
    Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03427.
    PubMed    
    
    
    October 2024
55. WAIRAGKAR N, Ismail AJ, Abouhussein DMN, Adeyeye MC, et al
    Regulatory reforms will boost African vaccine production and access.
    Nat Med. 2024 Oct 29. doi: 10.1038/s41591-024-03314.
    PubMed    
    
    
    
56. 
    Lassa vaccines to save lives, spare economies and assist in pandemic preparedness.
    Nat Med. 2024 Oct 11. doi: 10.1038/s41591-024-03332.
    PubMed    
    
    
    September 2024
57. NGUYEN DC, Hentenaar IT, Morrison-Porter A, Solano D, et al
    SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination.
    Nat Med. 2024 Sep 27. doi: 10.1038/s41591-024-03278.
    PubMed     Abstract available
    
    
    
58. WEBBY RJ
    The practical longevity of stockpiled A(H5N1) influenza vaccine.
    Nat Med. 2024 Sep 26. doi: 10.1038/s41591-024-03256.
    PubMed    
    
    
    August 2024
59. JOHANSEN ND, Vaduganathan M, Bhatt AS, Modin D, et al
    Electronic nudges for sustained influenza vaccination uptake in older adults: the nationwide randomized NUDGE-FLU-2 trial.
    Nat Med. 2024 Aug 30. doi: 10.1038/s41591-024-03202.
    PubMed     Abstract available
    
    
    
60. SMITH DRM, Turner J, Fahr P, Attfield LA, et al
    Health and economic impacts of Lassa vaccination campaigns in West Africa.
    Nat Med. 2024 Aug 28. doi: 10.1038/s41591-024-03232.
    PubMed     Abstract available
    
    
    
61. DEREJE N, Fallah MP, Ndembi N, Duga A, et al
    A community engagement framework to accelerate the uptake of malaria vaccines in Africa.
    Nat Med. 2024 Aug 22. doi: 10.1038/s41591-024-03193.
    PubMed    
    
    
    July 2024
62. SUN K, Bhiman JN, Tempia S, Kleynhans J, et al
    SARS-CoV-2 correlates of protection from infection against variants of concern.
    Nat Med. 2024 Jul 26. doi: 10.1038/s41591-024-03131.
    PubMed     Abstract available
    
    
    
63. TAQUET M, Dercon Q, Todd JA, Harrison PJ, et al
    The recombinant shingles vaccine is associated with lower risk of dementia.
    Nat Med. 2024 Jul 25. doi: 10.1038/s41591-024-03201.
    PubMed     Abstract available
    
    
    
64. KHURANA S, King LR, Manischewitz J, Posadas O, et al
    Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.
    Nat Med. 2024 Jul 16. doi: 10.1038/s41591-024-03189.
    PubMed     Abstract available
    
    
    
65. MAY M
    How mRNA is powering a personalized vaccine revolution.
    Nat Med. 2024 Jul 15. doi: 10.1038/d41591-024-00052.
    PubMed    
    
    
    
66. XU H, Zou K, Dent J, Wiens KE, et al
    Author Correction: Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Jul 9. doi: 10.1038/s41591-024-03176.
    PubMed    
    
    
    June 2024
67. ZHONG Y, Kang AYH, Tay CJX, Li HE, et al
    Publisher Correction: Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
    Nat Med. 2024 Jun 10. doi: 10.1038/s41591-024-03107.
    PubMed    
    
    
    
68. LI R, Shah PH, Stewart TF, Nam JK, et al
    Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
    Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03025.
    PubMed     Abstract available
    
    
    
69. LAZARUS JV, White TM, Wyka K, Ratzan SC, et al
    Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023.
    Nat Med. 2024;30:1559-1563.
    PubMed     Abstract available
    
    
    
70. CLIFF M, Welaga P, Mohammed N, Ansah P, et al
    Strategies for controlling pneumococcal disease and outbreaks during humanitarian emergencies.
    Nat Med. 2024;30:1515-1516.
    PubMed    
    
    
    May 2024
71. MENTZER AJ, Dilthey AT, Pollard M, Gurdasani D, et al
    High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
    Nat Med. 2024 May 13. doi: 10.1038/s41591-024-02944.
    PubMed     Abstract available
    
    
    April 2024
72. ZHONG Y, Kang AYH, Tay CJX, Li HE, et al
    Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02962.
    PubMed     Abstract available
    
    
    
73. SARAF A, Gurjar R, Kaviraj S, Kulkarni A, et al
    An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
    Nat Med. 2024 Apr 18. doi: 10.1038/s41591-024-02955.
    PubMed     Abstract available
    
    
    
74. ARNOLD C
    'Inverse vaccines' could treat autoimmune disease - from multiple sclerosis to celiac disease.
    Nat Med. 2024 Apr 10. doi: 10.1038/d41591-024-00024.
    PubMed    
    
    
    
75. YARCHOAN M, Gane EJ, Marron TU, Perales-Linares R, et al
    Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
    Nat Med. 2024 Apr 7. doi: 10.1038/s41591-024-02894.
    PubMed     Abstract available
    
    
    
76. 
    Systematic testing in cholera surveillance enhances vaccine impact and cost-effectiveness.
    Nat Med. 2024 Apr 3. doi: 10.1038/s41591-024-02907.
    PubMed    
    
    
    March 2024
77. O'LEARY K
    Going the extra mile to increase vaccine uptake.
    Nat Med. 2024 Mar 28. doi: 10.1038/d41591-024-00022.
    PubMed    
    
    
    
78. RAPPAPORT AR, Kyi C, Lane M, Hart MG, et al
    A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2024 Mar 27. doi: 10.1038/s41591-024-02851.
    PubMed     Abstract available
    
    
    
79. XU H, Zou K, Dent J, Wiens KE, et al
    Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Nat Med. 2024 Mar 5. doi: 10.1038/s41591-024-02852.
    PubMed     Abstract available
    
    
    February 2024
80. PERETTI-WATEL P, Verger P, Ward JK
    To understand mRNA vaccine hesitancy, stop calling the public anti-science.
    Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum